<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004118A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004118</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13592286</doc-number><date>20120822</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>40</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>40</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>40</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>40</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>4241391</main-classification><further-classification>5303879</further-classification><further-classification>5303873</further-classification><further-classification>435331</further-classification></classification-national><invention-title id="d0e43">CLOSTRIDIUM DIFFICILE ANTIBODIES</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61526031</doc-number><date>20110822</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Cassan</last-name><first-name>Robyn</first-name><address><city>Winnipeg</city><country>CA</country></address></addressbook><residence><country>CA</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only"><addressbook><last-name>Berry</last-name><first-name>Jody</first-name><address><city>Carlsbad</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="02" app-type="applicant" designation="us-only"><addressbook><last-name>Johnstone</last-name><first-name>Darrell</first-name><address><city>Winnipeg</city><country>CA</country></address></addressbook><residence><country>CA</country></residence></us-applicant><us-applicant sequence="03" app-type="applicant" designation="us-only"><addressbook><last-name>Toth</last-name><first-name>Derek</first-name><address><city>Dugald</city><country>CA</country></address></addressbook><residence><country>CA</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Cassan</last-name><first-name>Robyn</first-name><address><city>Winnipeg</city><country>CA</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Berry</last-name><first-name>Jody</first-name><address><city>Carlsbad</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Johnstone</last-name><first-name>Darrell</first-name><address><city>Winnipeg</city><country>CA</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Toth</last-name><first-name>Derek</first-name><address><city>Dugald</city><country>CA</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>CANGENE CORPORATION</orgname><role>03</role><address><city>Winnipeg</city><state>MB</state><country>CA</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Compositions and methods for the treatment or prevention of <i>Clostridium difficile </i>infection in a subject are provided. The compositions comprise antibodies to <i>Clostridium difficile </i>toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from <i>Clostridium difficile </i>bacterial infection.</p></abstract></us-patent-application>